Regulators of innate immunity as novel targets for panviral therapeutics

Current Opinion in Virology

Volumn 2, Issue 5, 2012, Pages 622-628

  Es Saad, Salwa ^a   Tremblay, Nicolas ^a   Baril, Martin ^a   Lamarre, Daniel ^a,b  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; HEPATITIS B VACCINE; IMIDAZOQUINOLINE DERIVATIVE; INTERFERON; ISATORIBINE; TOLL LIKE RECEPTOR AGONIST;

ADAPTIVE IMMUNITY; ARTICLE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INNATE IMMUNITY; PRIORITY JOURNAL; VIRUS INFECTION; WART VIRUS;

EID: 84867402015     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2012.08.009     Document Type: Review

References (56)

1. O. Takeuchi, and S. Akira Pattern recognition receptors and inflammation Cell 140 2010 805 820
2. Y.M. Loo, and M. Gale Jr. Immune signaling by RIG-I-like receptors Immunity 34 2011 680 692
3. F. Hou, L. Sun, H. Zheng, B. Skaug, Q.X. Jiang, and Z.J. Chen MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response Cell 146 2011 448 461
4. T. Kawai, and S. Akira Toll-like receptors and their crosstalk with other innate receptors in infection and immunity Immunity 34 2011 637 650
5. K. Eisenacher, and A. Krug Regulation of RLR-mediated innate immune signaling - it is all about keeping the balance Eur J Cell Biol 91 2012 36 47
6. S. Li, L. Wang, M. Berman, Y.Y. Kong, and M.E. Dorf Mapping a dynamic innate immunity protein interaction network regulating type I interferon production Immunity 35 2011 426 440
7. S. Hervas-Stubbs, J.L. Perez-Gracia, A. Rouzaut, M.F. Sanmamed, A. Le Bon, and I. Melero Direct effects of type I interferons on cells of the immune system Clin Cancer Res 17 2011 2619 2627
8. B.X. Wang, and E.N. Fish The yin and yang of viruses and interferons Trends Immunol 33 2012 190 197
9. Y. Gao, B. Majchrzak-Kita, E.N. Fish, and J.L. Gommerman Dynamic accumulation of plasmacytoid dendritic cells in lymph nodes is regulated by interferon-beta Blood 114 2009 2623 2631
10. C.J. Desmet, and K.J. Ishii Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination Nat Rev Immunol 12 2012 479 491
11. H. Kato, K. Takahasi, and T. Fujita RIG-I-like receptors: cytoplasmic sensors for non-self RNA Immunol Rev 243 2011 91 98
12. L.A. O'Neill, F.J. Sheedy, and C.E. McCoy MicroRNAs: the fine-tuners of Toll-like receptor signalling Nat Rev Immunol 11 2011 163 175
13. T. Kondo, T. Kawai, and S. Akira Dissecting negative regulation of Toll-like receptor signaling Trends Immunol 2012
14. H.J. Ramos, and M. Gale Jr. RIG-I like receptors and their signaling crosstalk in the regulation of antiviral immunity Curr Opin Virol 1 2011 167 176
15. Y. Kumaki, C.W. Day, M.K. Wandersee, B.P. Schow, J.S. Madsen, D. Grant, J.P. Roth, D.F. Smee, L.M. Blatt, and D.L. Barnard Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells Biochem Biophys Res Commun 371 2008 110 113
16. L. Gao, S. Yu, Q. Chen, Z. Duan, J. Zhou, C. Mao, D. Yu, W. Zhu, J. Nie, and Y. Hou A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits Vaccine 28 2010 4445 4451
17. A.C. Kalil, M.P. Devetten, S. Singh, B. Lesiak, D.P. Poage, K. Bargenquast, P. Fayad, and A.G. Freifeld Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases Clin Infect Dis 40 2005 764 766
18. J.G. Julander, J. Ennis, J. Turner, and J.D. Morrey Treatment of yellow fever virus with an adenovirus-vectored interferon DEF201, in a hamster model Antimicrob Agents Chemother 55 2011 2067 2073
19. P.B. Jahrling, T.W. Geisbert, J.B. Geisbert, J.R. Swearengen, M. Bray, N.K. Jaax, J.W. Huggins, J.W. LeDuc, and C.J. Peters Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections J Infect Dis 179 Suppl. 1 1999 S224 S234
20. S.M. Alavian, B. Behnava, and S.V. Tabatabaei Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis Eur J Clin Pharmacol 66 2010 1071 1079
21. R. Flisiak, and I. Flisiak Albinterferon-alpha 2b: a new treatment option for hepatitis C Expert Opin Biol Ther 10 2010 1509 1515
22. Ashour MKF: Clinical trial of the efficacy, dosing, safety and tolerability of Y-shaped pegylated interferon (YPEG-IFNα-2a) plus ribavirin in egyptian patients with untreated chronic hepatitis C. In American Association for the study of liver diseases. San Francisco, CA; 2011.
23. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, and A.J. Muir Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
24. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, C. O'Huigin, J. Kidd, K. Kidd, S.I. Khakoo, and G. Alexander Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
25. A.J. Muir, M.L. Shiffman, A. Zaman, B. Yoffe, A. de la Torre, S. Flamm, S.C. Gordon, P. Marotta, J.M. Vierling, and J.C. Lopez-Talavera Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection Hepatology 52 2010 822 832
26. R.P. Donnelly, and S.V. Kotenko Interferon-lambda: a new addition to an old family J Interferon Cytokine Res 30 2010 555 564
27. M. Hedayat, M.G. Netea, and N. Rezaei Targeting of Toll-like receptors: a decade of progress in combating infectious diseases Lancet Infect Dis 11 2011 702 712
28. A.J. Wagstaff, and C.M. Perry Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions Drugs 67 2007 2187 2210
29. P.J. Pockros, D. Guyader, H. Patton, M.J. Tong, T. Wright, J.G. McHutchison, and T.C. Meng Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies J Hepatol 47 2007 174 182
30. B. Kronenberger, and S. Zeuzem Current and future treatment options for HCV Ann Hepatol 8 2009 103 112
31. J.F. Bergmann, J. de Bruijne, D.M. Hotho, R.J. de Knegt, A. Boonstra, C.J. Weegink, A.A. van Vliet, J. van de Wetering, S.P. Fletcher, and L.A. Bauman Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV Aliment Pharmacol Ther 34 2011 443 453
32. A.P. Vicari, T. Schmalbach, J. Lekstrom-Himes, M.L. Morris, M.J. Al-Adhami, C. Laframboise, P. Leese, A.M. Krieg, S.M. Efler, and H.L. Davis Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist Antivir Ther 12 2007 741 751
33. A. Muir, R. Ghalib, E. Lawitz, K. Patel, M. Rodriguez-torres, A. Sheikh, S. Sapp, R. Taylor, A. Bexon, and T. Sullivan A phase 1, multi-center, randomized, placebo-controlled, dose-escalation study of IMO-2125, a TLR9 agonist, in hepatitis C nonresponders EASL 45th Annual Meeting April Vienna, Austria 2010
34. N.J. Horscroft, D.C. Pryde, and H. Bright Antiviral applications of Toll-like receptor agonists J Antimicrob Chemother 67 2012 789 801
35. D. Guyader, P. Bogomolov, Z. Kobalava, V. Moiseev, J. Szlavik, B. Astruc, I. Varkonyi, T. Sullivan, K. Horgan, and A. Bexon IMO-2125 plus ribavirin gives substantial first-dose viral load reductions, cumulative antiviral effect, is well tolerated in naïve genotype 1 HCV patients: a phase 1 trial EASL 46th Annual Meeting March Berlin, Germany 2011
36. V. Mata-Haro, C. Cekic, M. Martin, P.M. Chilton, C.R. Casella, and T.C. Mitchell The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4 Science 316 2007 1628 1632
37. A.L. Gavin, K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, and D. Nemazee Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling Science 314 2006 1936 1938
38. D. van Duin, R. Medzhitov, and A.C. Shaw Triggering TLR signaling in vaccination Trends Immunol 27 2006 49 55
39. M. Kundi New hepatitis B vaccine formulated with an improved adjuvant system Expert Rev Vaccines 6 2007 133 140
40. T.F. Schwarz Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix Adv Ther 26 2009 983 998
41. A.M. Didierlaurent, S. Morel, L. Lockman, S.L. Giannini, M. Bisteau, H. Carlsen, A. Kielland, O. Vosters, N. Vanderheyde, and F. Schiavetti AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity J Immunol 183 2009 6186 6197
42. A.M. Harandi, G. Davies, and O.F. Olesen Vaccine adjuvants: scientific challenges and strategic initiatives Expert Rev Vaccines 8 2009 293 298
43. H.K. Talbot, M.T. Rock, C. Johnson, L. Tussey, U. Kavita, A. Shanker, A.R. Shaw, and D.N. Taylor Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin PLoS ONE 5 2010 e14442
44. D.N. Taylor, J.J. Treanor, E.A. Sheldon, C. Johnson, S. Umlauf, L. Song, U. Kavita, G. Liu, L. Tussey, and K. Ozer Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response Vaccine 2012
45. J.J. Treanor, D.N. Taylor, L. Tussey, C. Hay, C. Nolan, T. Fitzgerald, G. Liu, U. Kavita, L. Song, and I. Dark Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults Vaccine 28 2010 8268 8274
46. L. Jouan, L. Chatel-Chaix, P. Melancon, I.G. Rodrigue-Gervais, V.A. Raymond, S. Selliah, M. Bilodeau, N. Grandvaux, and D. Lamarre Targeted impairment of innate antiviral responses in the liver of chronic hepatitis C patients J Hepatol 2011
47. L. Jouan, P. Melancon, I.G. Rodrigue-Gervais, V.A. Raymond, S. Selliah, G. Boucher, M. Bilodeau, N. Grandvaux, and D. Lamarre Distinct antiviral signaling pathways in primary human hepatocytes and their differential disruption by HCV NS3 protease J Hepatol 52 2010 167 175
48. I.G. Rodrigue-Gervais, L. Jouan, G. Beaule, D. Sauve, J. Bruneau, B. Willems, R.P. Sekaly, and D. Lamarre Poly(I:C) and lipopolysaccharide innate sensing functions of circulating human myeloid dendritic cells are affected in vivo in hepatitis C virus-infected patients J Virol 81 2007 5537 5546
49. I. Botos, D.M. Segal, and D.R. Davies The structural biology of Toll-like receptors Structure 19 2011 447 459
50. R.C. Ireton, and M. Gale Jr. RIG-I like receptors in antiviral immunity and therapeutic applications Viruses 3 2011 906 919
51. F. Jiang, A. Ramanathan, M.T. Miller, G.Q. Tang, M. Gale Jr., S.S. Patel, and J. Marcotrigiano Structural basis of RNA recognition and activation by innate immune receptor RIG-I Nature 479 2011 423 427
52. D. Luo, S.C. Ding, A. Vela, A. Kohlway, B.D. Lindenbach, and A.M. Pyle Structural insights into RNA recognition by RIG-I Cell 147 2011 409 422
53. K.V. Chakravarthy, A.C. Bonoiu, W.G. Davis, P. Ranjan, H. Ding, R. Hu, J.B. Bowzard, E.J. Bergey, J.M. Katz, and P.R. Knight Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication Proc Natl Acad Sci U S A 107 2010 10172 10177
54. J.M. Luke, G.G. Simon, J. Soderholm, J.S. Errett, J.T. August, M. Gale Jr., C.P. Hodgson, and J.A. Williams Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine J Virol 85 2011 1370 1383
55. K. Kobiyama, F. Takeshita, K.J. Ishii, S. Koyama, T. Aoshi, S. Akira, A. Sakaue-Sawano, A. Miyawaki, Y. Yamanaka, and H. Hirano A signaling polypeptide derived from an innate immune adaptor molecule can be harnessed as a new class of vaccine adjuvant J Immunol 182 2009 1593 1601
56. E. Gottwein, and B.R. Cullen Viral and cellular microRNAs as determinants of viral pathogenesis and immunity Cell Host Microbe 3 2008 375 387